Subjects with low-density lipoprotein cholesterol < @ mg/dL and heightened immune activation ( % CD@ ( + ) CD@ ( + ) HLA-DR ( + ) @ % , or plasma high-sensitivity C-reactive protein @ mg/L ) were randomized to receive rosuvastatin or placebo .